Ingram (TX)
{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~85 mi. (San Antonio, Texas, +192 more cities)
facility
Texas Oncology - San Antonio Medical Center
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
city
~85 mi. (San Antonio, Texas, +454 more cities)
facility
Children's Hospital of San Antonio, +2 more facilities
condition
Classical Hodgkin Lymphoma
drug
brentuximab vedotin, +7 more drugs
drug type
chemotherapy, +3 more types
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~85 mi. (San Antonio, Texas, +147 more cities)
facility
Texas Oncology-San Antonio Medical Center ( Site 8002)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~85 mi. (San Antonio, Texas, +93 more cities)
facility
Urology of San Antonio ( Site 0020)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
city
~85 mi. (San Antonio, Texas, +271 more cities)
facility
Urology San Antonio P.A.
condition
Prostate Adenocarcinoma
drug
docetaxel, +2 more drugs
drug type
chemotherapy, +2 more types
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
city
~85 mi. (San Antonio, Texas, +825 more cities)
facility
University of Texas Health Science Center at San Antonio, +1 more facility
biomarker
AKT1 Mutation, +91 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
adavosertib, +26 more drugs
drug type
immunotherapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~85 mi. (San Antonio, Texas, +260 more cities)
facility
Cancer Therapy and Research Center CTRC at UTHSCSA
biomarker
ERBB2 Amplification, +1 more biomarker
condition
Invasive Breast Carcinoma
drug
ado-trastuzumab emtansine, +1 more drug
drug type
immunotherapy, +1 more type